Skip to main content

Ironwood Pharma (IRWD) Gets a Hold from Wells Fargo

Tipranks - Tipranks - Wed Nov 12, 2025

Wells Fargo analyst maintained a Hold rating on Ironwood Pharma today and set a price target of $3.00.

Meet Your ETF AI Analyst

In a report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.50 price target.

See the top stocks recommended by analysts >>

Based on Ironwood Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $122.06 million and a net profit of $95.96 million. In comparison, last year the company earned a revenue of $91.59 million and had a net profit of $3.65 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRWD in relation to earlier this year. Most recently, in August 2025, Martini Gregory S., the CFO of IRWD sold 1,265.00 shares for a total of $1,062.60.

Read More on IRWD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).